Multimedication Guidelines: Assessment of the Size of the Target Group for Medication Review and Description of the Frequency of Their Potential Drug Safety Problems with Routine Data
Lappe V, Dinh TS, Harder S, Brueckle M-S, Fessler J, Marschall U, Muth C, Schubert I (2022)
Pharmacoepidemiology 1(1): 12-25.
Zeitschriftenaufsatz
| Veröffentlicht | Englisch
Download
pharmacoepidemiology-01-00002-v2.pdf
703.07 KB
Autor*in
Lappe, Veronika;
Dinh, Truc Sophia;
Harder, Sebastian;
Brueckle, Maria-Sophie;
Fessler, Joachim;
Marschall, Ursula;
Muth, ChristianeUniBi;
Schubert, Ingrid
Abstract / Bemerkung
(1) Background: About 10 years ago, several guidelines for the better management of patients with polypharmacy were issued. A central issue is the definition of the target group. The primary aim of this study is therefore to assess the size of the target group, applying the criteria of the German guidelines. A further aim is to describe the frequency of occurrence of medication safety issues for patients of the target group.
(2) Methods: The study is based on administrative data of one large statutory health insurer in Germany (n = 9,012,523).
(3) Results: The criteria of multimorbidity (at least three chronic diseases) and utilization of five or more concurrent drugs over at least 91 days is fulfilled by 14.1% of the insured patients, or almost 1.3 million persons. About 5% of this multimorbid and poly-medicated population fulfilled at least three of out of five additional occasion-related criteria. Medication safety issues occur frequently: treatment prevalence with potentially inadequate medication, QT-drugs, benzodiazepine or Z-drugs and proton pump inhibitors was 30.4%, 28.9%, 11.1% and 52.4%, respectively.
(4) Conclusions: The analysis shows the scope of patients eligible for a structured medication review and demonstrates the relevance for counselling based on the high percentage potentially at risk due to medication therapy safety problems.
(2) Methods: The study is based on administrative data of one large statutory health insurer in Germany (n = 9,012,523).
(3) Results: The criteria of multimorbidity (at least three chronic diseases) and utilization of five or more concurrent drugs over at least 91 days is fulfilled by 14.1% of the insured patients, or almost 1.3 million persons. About 5% of this multimorbid and poly-medicated population fulfilled at least three of out of five additional occasion-related criteria. Medication safety issues occur frequently: treatment prevalence with potentially inadequate medication, QT-drugs, benzodiazepine or Z-drugs and proton pump inhibitors was 30.4%, 28.9%, 11.1% and 52.4%, respectively.
(4) Conclusions: The analysis shows the scope of patients eligible for a structured medication review and demonstrates the relevance for counselling based on the high percentage potentially at risk due to medication therapy safety problems.
Erscheinungsjahr
2022
Zeitschriftentitel
Pharmacoepidemiology
Band
1
Ausgabe
1
Seite(n)
12-25
Urheberrecht / Lizenzen
eISSN
2813-0618
Page URI
https://pub.uni-bielefeld.de/record/2963967
Zitieren
Lappe V, Dinh TS, Harder S, et al. Multimedication Guidelines: Assessment of the Size of the Target Group for Medication Review and Description of the Frequency of Their Potential Drug Safety Problems with Routine Data. Pharmacoepidemiology. 2022;1(1):12-25.
Lappe, V., Dinh, T. S., Harder, S., Brueckle, M. - S., Fessler, J., Marschall, U., Muth, C., et al. (2022). Multimedication Guidelines: Assessment of the Size of the Target Group for Medication Review and Description of the Frequency of Their Potential Drug Safety Problems with Routine Data. Pharmacoepidemiology, 1(1), 12-25. https://doi.org/10.3390/pharma1010002
Lappe, Veronika, Dinh, Truc Sophia, Harder, Sebastian, Brueckle, Maria-Sophie, Fessler, Joachim, Marschall, Ursula, Muth, Christiane, and Schubert, Ingrid. 2022. “Multimedication Guidelines: Assessment of the Size of the Target Group for Medication Review and Description of the Frequency of Their Potential Drug Safety Problems with Routine Data”. Pharmacoepidemiology 1 (1): 12-25.
Lappe, V., Dinh, T. S., Harder, S., Brueckle, M. - S., Fessler, J., Marschall, U., Muth, C., and Schubert, I. (2022). Multimedication Guidelines: Assessment of the Size of the Target Group for Medication Review and Description of the Frequency of Their Potential Drug Safety Problems with Routine Data. Pharmacoepidemiology 1, 12-25.
Lappe, V., et al., 2022. Multimedication Guidelines: Assessment of the Size of the Target Group for Medication Review and Description of the Frequency of Their Potential Drug Safety Problems with Routine Data. Pharmacoepidemiology, 1(1), p 12-25.
V. Lappe, et al., “Multimedication Guidelines: Assessment of the Size of the Target Group for Medication Review and Description of the Frequency of Their Potential Drug Safety Problems with Routine Data”, Pharmacoepidemiology, vol. 1, 2022, pp. 12-25.
Lappe, V., Dinh, T.S., Harder, S., Brueckle, M.-S., Fessler, J., Marschall, U., Muth, C., Schubert, I.: Multimedication Guidelines: Assessment of the Size of the Target Group for Medication Review and Description of the Frequency of Their Potential Drug Safety Problems with Routine Data. Pharmacoepidemiology. 1, 12-25 (2022).
Lappe, Veronika, Dinh, Truc Sophia, Harder, Sebastian, Brueckle, Maria-Sophie, Fessler, Joachim, Marschall, Ursula, Muth, Christiane, and Schubert, Ingrid. “Multimedication Guidelines: Assessment of the Size of the Target Group for Medication Review and Description of the Frequency of Their Potential Drug Safety Problems with Routine Data”. Pharmacoepidemiology 1.1 (2022): 12-25.
Alle Dateien verfügbar unter der/den folgenden Lizenz(en):
Creative Commons Namensnennung 4.0 International Public License (CC-BY 4.0):
Volltext(e)
Name
pharmacoepidemiology-01-00002-v2.pdf
703.07 KB
Access Level
Open Access
Zuletzt Hochgeladen
2022-10-17T13:05:11Z
MD5 Prüfsumme
dd04fb574806b8dff5c153b32dbfbe2e